Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy / Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Cristina Papayannidis, Ilaria Iacobucci, Claudia Venturi, Manuela Mancini, Elisa Leo, Hana Klamova, Stefania Paolini, Domenico Russo, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli. - In: BLOOD. - ISSN 0006-4971. - ELETTRONICO. - 122:21(2013), pp. 380-380. [10.1182/blood.V122.21.380.380]
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy
Simona Soverini;Caterina De Benedittis;Fausto Castagnetti;Gabriele Gugliotta;Francesca Palandri;Cristina Papayannidis;Ilaria Iacobucci;Claudia Venturi;Manuela Mancini;Elisa Leo;Stefania Paolini;Domenico Russo;Gianantonio Rosti;Michele Baccarani;Michele Cavo;Giovanni Martinelli
2013
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.